Clinical Trial Detail

NCT ID NCT03285607
Title MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Recruitment Withdrawn
Gender
Phase Phase I
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST